Unit of Clinical Alcohol Research (UCAR), University of Southern Denmark, Denmark; Department of Psychiatry, Odense University Hospital, Region of Southern Denmark, Odense, Denmark; Brain Research-Inter-Disciplinary Guided Excellence (BRIDGE), Department of Clinical Research, University of Southern Denmark, Odense, Denmark; Center for Digital Psychiatry (CDP), Mental Health Services in the Region of Southern Denmark, Denmark.
Unit of Clinical Alcohol Research (UCAR), University of Southern Denmark, Denmark; Unit of Epidemiology of Psychiatric Conditions, Substance use and Social Environment (EPiCSS), Department of Global Public Health, Karolinska Institute, Sweden.
Neurosci Biobehav Rev. 2023 Aug;151:105185. doi: 10.1016/j.neubiorev.2023.105185. Epub 2023 Apr 28.
Oxytocin is gaining traction in the treatment of various substance use disorders (SUD). We performed a systematic review assessing the efficacy of oxytocin for treating different SUD. The electronic databases MEDLINE, EMBASE, CENTRAL, and the Cochrane Database of Systematic Reviews were searched for randomized controlled trials examining the effects of oxytocin vs. placebo in SUD samples. Quality assessment was conducted using a Cochrane validated checklist. A total of 17 trials with unique samples were identified. These were conducted on participants with SUD involving alcohol (n = 5), opioids (n = 3), opioids and/or cocaine/other stimulants (n = 3), cannabis (n = 2), or nicotine (n = 4). Across the SUD-groups, oxytocin reduced withdrawal symptoms (3/5 trials), negative emotional states (4/11 trials), cravings (4/11 trials), cue-induced cravings (4/7 trials), and consumption (4/8 trials). Sixteen trials had an overall considerable risk of bias. In conclusion, although oxytocin showed some promising therapeutic effects, the findings are too inconsistent and the trials too heterogeneous to derive any firm conclusions. Sounder methodological and well-powered trials are warranted.
催产素在治疗各种物质使用障碍（SUD）方面越来越受到关注。我们进行了一项系统评价，评估了催产素治疗不同 SUD 的疗效。电子数据库 MEDLINE、EMBASE、CENTRAL 和 Cochrane 系统评价数据库被用来搜索关于催产素与安慰剂在 SUD 样本中比较效果的随机对照试验。使用 Cochrane 验证的清单进行了质量评估。确定了 17 项具有独特样本的试验。这些试验是在涉及酒精（n=5）、阿片类药物（n=3）、阿片类药物和/或可卡因/其他兴奋剂（n=3）、大麻（n=2）或尼古丁（n=4）的 SUD 参与者中进行的。在 SUD 组中，催产素减少了戒断症状（3/5 项试验）、负性情绪状态（4/11 项试验）、渴求（4/11 项试验）、线索诱发的渴求（4/7 项试验）和消费（4/8 项试验）。16 项试验的总体偏倚风险较高。总之，尽管催产素显示出一些有希望的治疗效果，但结果太不一致，试验太异质，无法得出任何确定的结论。需要进行更可靠的方法学和更有力的试验。
